These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27752157)

  • 21. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
    Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
    Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
    Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
    Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer.
    Laas E; Ballester M; Cortez A; Gonin J; Daraï E; Graesslin O
    Gynecol Oncol; 2014 May; 133(2):205-10. PubMed ID: 24556060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ER and PR expression and survival after endometrial cancer.
    Smith D; Stewart CJR; Clarke EM; Lose F; Davies C; Armes J; Obermair A; Brennan D; Webb PM; Nagle CM; Spurdle AB
    Gynecol Oncol; 2018 Feb; 148(2):258-266. PubMed ID: 29217139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status.
    Wang D; Konishi I; Koshiyama M; Mandai M; Nanbu Y; Ishikawa Y; Mori T; Fujii S
    Cancer; 1993 Nov; 72(9):2628-37. PubMed ID: 8104681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer.
    Maeda K; Tsuda H; Hashiguchi Y; Yamamoto K; Inoue T; Ishiko O; Ogita S
    Hum Pathol; 2002 Apr; 33(4):386-91. PubMed ID: 12055672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma With Clear Cell Change, and Clear Cell Carcinoma.
    Lim D; Ip PP; Cheung AN; Kiyokawa T; Oliva E
    Am J Surg Pathol; 2015 Aug; 39(8):1061-9. PubMed ID: 25871622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
    Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.
    Rambau P; Kelemen LE; Steed H; Quan ML; Ghatage P; Köbel M
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study of estrogen and progesterone receptors in endometrial carcinoma].
    Chen Y; Peng Z
    Hua Xi Yi Ke Da Xue Xue Bao; 2000 Mar; 31(1):98-100. PubMed ID: 12501628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Estrogen and progesterone receptors in endometrial carcinoma].
    Guo Y; Dang Q
    Zhonghua Fu Chan Ke Za Zhi; 1997 Jul; 32(7):418-21. PubMed ID: 9639729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
    Li M; Zhao L; Shen D; Li X; Wang J; Wei L
    Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C; Wejaranayang C; Vipupinyo C
    J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma.
    Yadav A; Sistla A; Swain M; Gowrishankar S; Padua M; Modi T; Himabindu R; Agarwal N; Kulkarni A; Bhandari T; Vudayaraju H; Chinnababu ; Reddy VA
    Indian J Pathol Microbiol; 2024; 67(1):62-67. PubMed ID: 38358190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of epithelial membrane antigen overexpression in hyperplastic and malignant endometrium and its relationship with steroid hormone receptor expression.
    Kir G; Cetiner H; Gurbuz A; Karateke A
    Eur J Gynaecol Oncol; 2004; 25(4):502-5. PubMed ID: 15285315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study on expression of PCNA and estrogen, progesterone receptors in endometrial carcinoma].
    Chen YP; Shen M; Chen C
    Hunan Yi Ke Da Xue Xue Bao; 2001 Apr; 26(2):123-5. PubMed ID: 12536641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
    Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
    Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
    Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
    Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.